Acute Risk Monitoring for Oncology Therapy Regimen (ARMOR)

Patients receiving cancer therapy at University of California, San Francisco (UCSF)

All adults undergoing systemic cancer-related therapy from July 2017 to March 2024 at any UCSF outpatient, infusion center with available OP-35 data.

其他：Medical record review

Retrospective chart reviews for data collection will be conducted.

Area under the receiver operating characteristic curve (AUROC) for OP-35 prediction model.

UCSF patients receiving infusion systemic therapy had clinical data incorporated into machine learning (ML) models to predict risk of Centers for Medicare & Medicaid Services Chemotherapy Measure (OP-35) qualifying acute care events within 30 days of infusion. Models included variables such as cancer diagnosis, therapeutic agents, and laboratory values. Three ML approaches were employed to train models in predicting OP-35 events. Models were trained and retrospectively validated on data from July 7, 2017, to February 11, 2021, and prospectively validated on 2 cohorts: April 17, 2023, to October 29, 2023 (PV1) and February 19, 2024, to March 31, 2024 (PV2) to generate a validation AUROC. The initial prospective validation occurred over a pre-planned period with the assumption of a 2% event rate, based on the model development data, with an alpha of 0.05 and 84% power to detect an AUROC of 0.75, requiring a sample size of at least 8000 infusions.